BioMinds Advisors offers executive-level advisory and fractional services to small to mid-size companies in the Life Sciences industry, specializing in two key areas: commercial strategy and alliance management. We provide needed support in shaping commercial strategies, orchestrating go-to-market plans, preparing for asset launches, and assembling the first commercial team. On the alliance management front, we diagnose partnership health and implement best-in-class alliance management competencies to unlock the full potential of partnerships.Our expertise spans commercial strategy, marketing, sales execution, and alliance management, coupled with a robust network of cross-functional experts, all aimed at positioning our clients for success.

Leadership & Results• Lead global team of 50 marketing and sales FTEs and hired 15 FTEs over two years. • Grew top-line global medical business >40% in two years.• Managed medical and pharmaceutical business global P&L.Resource Realignment & Growth Strategy• Instituted marketing organization focused on addressing unsolved market problems, evaluating disruptive and innovative technologies, assessing therapeutic areas, and providing direction to sales force.• Segmented business into distinct teams based on end use of materials, resulting in greater focus/expertise.• Developed strategy for each segment (medical devices, orthopedic implants, and long-acting drug delivery).Innovation• Championed joint development with startup company possessing technology with potential to grow key medical segment significantly and disrupt current value chain.• Secured grant from Bill & Melinda Gates Foundation for development of refillable contraceptive device.

• Led team of 12 FTEs to develop launch strategies, lifecycle management plans, and forecasts for portfolio of ten biosimilar products (marketing, value/access/policy, forecasting, market research, and competitive intelligence).• Collaborated with development, med affairs, operations, regulatory, finance, and IP law to inform go-to-market plans.• Identified potential pipeline biosimilar programs to pursue with cross-functional team.• Directed ideation and development of lifecycle management recommendations to differentiate Amgen biosimilars.

Led team of 120 field staff, including sales representatives, district managers, regional directors, and nurse educators.

XGEVA & Vectibix US Marketing Lead• Managed two key growth brands and corresponding brand teams.• Led brand plan development, brand forecasts, pricing decisions, and contract development and implementation.• Spearheaded development and implementation of XGEVA attitudinal segmentation to tailor messaging to customers.• Led growth of XGEVA sales by 30% to blockbuster status ($1B), as well as growth of Vectibix sales 40%, both in two years.• Recognized as Marketing Coach of the Year

• Managed, developed, and coached team of nine sales professionals in Los Angeles/Santa Barbara/Hawaii district.• Accountable for $120M annual revenue representing five oncology supportive care and targeted therapy products.• District ranked first nationally (out of 48 districts) based on 2013 cumulative sales.• Earned Team Excellence Award. Won Chairman’s Circle.

• Led team of 45 marketing operations and field operations employees. Led key strategic initiatives supporting US commercial organization. Provided cross-business unit insights into operational performance.

• Led seven-month diagnostic and cross-functional redesign effort to improve Amgen’s alliance management capability.• Analyzed potential healthcare reform impact to inform Amgen’s position in emerging healthcare reform legislation.• Received CEO Impact Award.

Maximized corporate value, developed growth strategies, and led organizational change. * Managed development of five-year corporate strategy for leading global biopharmaceutical company. * Evaluated M&A, financial policy, and cost reduction opportunities. Maximized total shareholder return and identified $1B in cost reduction opportunities. Managed five-year type 2 diabetes franchise strategy development for US biotech company. * Defined key commercial and clinical opportunities to optimize drug portfolio performance, yielding incremental $200M (12% increase) in 2012 revenue. * Led transformation and two post-merger integration planning and implementation efforts focused on optimizing Marketing and Sales.

Developed, presented, and implemented marketing strategies for clients in media/entertainment and consumer products industries.